

Sara Pratesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8880478/publications.pdf>

Version: 2024-02-01

27
papers

728
citations

623188

14
h-index

552369

26
g-index

27
all docs

27
docs citations

27
times ranked

1082
citing authors

#	ARTICLE	IF	CITATIONS
1	Elevated IL-19 Serum Levels in Patients With Pernicious Anemia and Autoimmune Gastritis. <i>Frontiers in Immunology</i> , 2022, 13, 887256.	2.2	7
2	Neuroprotection induced by dexamipexole delays disease progression in a mouse model of progressive multiple sclerosis. <i>British Journal of Pharmacology</i> , 2020, 177, 3342-3356.	2.7	8
3	The percentage of patients achieving complete remission of urticaria increases with repeated courses of treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 339-340.	2.0	9
4	Neuroimmunological characterization of a mouse model of primary progressive experimental autoimmune encephalomyelitis and effects of immunosuppressive or neuroprotective strategies on disease evolution. <i>Experimental Neurology</i> , 2019, 322, 113065.	2.0	12
5	T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis. <i>Frontiers in Immunology</i> , 2019, 9, 3113.	2.2	10
6	Decreased circulating lymphatic endothelial progenitor cells in digital ulcer-complicated systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 575-577.	0.5	8
7	The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2065-2072.e2.	2.0	18
8	Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleichâ€™s Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 1198.	2.2	14
9	Post onset, oral rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses. <i>Neuropharmacology</i> , 2017, 117, 74-84.	2.0	23
10	IL-10â€™-Producing Infliximab-Specific T Cells Regulate the Antidrug T Cell Response in Exposed Patients. <i>Journal of Immunology</i> , 2017, 199, 1283-1289.	0.4	13
11	Angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis. <i>PLoS ONE</i> , 2017, 12, e0183102.	1.1	32
12	Dermatophagoides pteronyssinus group 2 allergen bound to 8-OH modified adenine reduces the Th2-mediated airway inflammation without inducing a Th17 response and autoimmunity. <i>Molecular Immunology</i> , 2016, 77, 60-70.	1.0	4
13	How the immune system responds to therapeutic biological agents. <i>Journal of International Medical Research</i> , 2016, 44, 38-42.	0.4	13
14	Hypersensitivity Reactions to Biologicals: True Allergy?. <i>Current Treatment Options in Allergy</i> , 2016, 3, 147-157.	0.9	4
15	An overview on safety of monoclonal antibodies. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 576-581.	1.1	18
16	Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound. <i>Brain, Behavior, and Immunity</i> , 2015, 50, 78-86.	2.0	48
17	Pharmacological NAD-Boosting Strategies Improve Mitochondrial Homeostasis in Human Complex Iâ€™ Mutant Fibroblasts. <i>Molecular Pharmacology</i> , 2015, 87, 965-971.	1.0	26
18	Treatment with 8â€™-OH â€™-modified adenine (TLR 7 ligand)â€™ allergen conjugates decreases T helper type 2â€™-oriented murine airway inflammation. <i>Immunology</i> , 2015, 145, 570-582.	2.0	7

#	ARTICLE	IF	CITATIONS
19	Manifestations of Antidrug Antibodies Response: Hypersensitivity and Infusion Reactions. <i>Journal of Interferon and Cytokine Research</i> , 2014, 34, 946-952.	0.5	34
20	Stable Conjugates Between A Novel Toll-Like Receptor 7 Ligand and Protein Allergens As Modulators Of Th2 Responses In Vitro and In Vivo. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, AB291.	1.5	0
21	Assays and Strategies for Immunogenicity Assessment of Biological Agents. <i>Drug Development Research</i> , 2014, 75, S4-6.	1.4	19
22	A novel allergen-adjuvant conjugate suitable for specific immunotherapy of respiratory allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 84-92.e6.	1.5	13
23	Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. <i>Clinical and Experimental Allergy</i> , 2013, 43, n/a-n/a.	1.4	61
24	Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab. <i>International Archives of Allergy and Immunology</i> , 2012, 159, 321-326.	0.9	59
25	Skin testing and infliximab-specific antibodies detection as a combined strategy for preventing infusion reaction. <i>Internal and Emergency Medicine</i> , 2012, 7, 77-79.	1.0	24
26	The TLR7 Ligand 9-Benzyl-2-Butoxy-8-Hydroxy Adenine Inhibits IL-17 Response by Eliciting IL-10 and IL-10-Inducing Cytokines. <i>Journal of Immunology</i> , 2011, 186, 4707-4715.	0.4	34
27	Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 657-661.	2.7	210